Growing evidence indicated that psoriasis is strongly associated with IL-17A, and clinically, the monoclonal antibodies to IL-17A or its receptor IL-17R showed a dramatic effect against psoriasis [2–4, 6–12]. This evidence concerns the gene IL17A and psoriasis.